Why CRBP rose 21.0% on Sep 14 2026: positive phase 1b data
CRBP+21.0%on Mon Sep 14 2026
Corbus Pharmaceuticals Holdings, Inc. was up 21.0% on the day at $9.97, ranked #2 on 984× its usual five-minute volume, when TapeRank recorded this spike at 07:31 ET during the pre-market session.
WHAT THE ROW LOOKED LIKE
LAST9.97
DAY▲ 21.0%
5 MIN▲ 8.71%
5M RVOL984×
5M $VOL$2.8M
FLOAT*18.7M
RANK#2
SESSIONPRE-MARKET
* FLOAT IS SHARES OUTSTANDING; TRUE FREE FLOAT IS NOT AVAILABLE
AI VERDICT
JUSTIFIEDCONFIDENCE4/5
Corbus reported positive, statistically significant Phase 1b topline data for its oral obesity candidate CRB-913, showing meaningful dose-dependent weight loss versus placebo in a 254-patient trial. The stock is up 18% pre-market on very heavy volume, consistent with a clinically de-risking readout in the hot obesity drug space.
WHYAn 18% move on positive, statistically significant Phase 1b efficacy data in a small-float obesity biotech is proportionate given how binary and closely watched such readouts are.
ANALYZED 07:30 ET · <1 MIN AGO · ANTHROPIC/CLAUDE-SONNET-5
FILINGS · 24H BEFORE THE MOVE
SESSION LEVELS AT CAPTURE
VWAP9.04
HOD10.19
LOD5.57
OR HIGH—
OR LOW—
PREV CLOSE8.24
PM HIGH10.19
PM LOW5.57
GAP▲ 1.70%
— MEANS THE LEVEL DID NOT EXIST YET AT THAT INSTANT, NOT ZERO